A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)

HIV-1-infection Clinical Trial

Official title:

EHVA T02 (European HIV Vaccine Alliance Therapeutic Trial 02)/ANRS VRI07: A Phase II Randomised, Placebo-controlled Trial of Vedolizumab With or Without Therapeutic HIV MVA Vaccine in Individuals Who Started Antiretrovirals During Primary or Chronic Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04120415
• Other study ID #: EHVA T02/ANRS VRI07
• Status: Completed
• Phase: Phase 2
• Start date: June 21, 2022
• Est. completion date: July 12, 2023

Study information

• Verified date: July 2023
• Source: ANRS, Emerging Infectious Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

EHVA T02 is an international, phase II, double-blind study to evaluate two experimental arms each compared to placebo control in HIV-1 positive participants to see if either has a clinically relevant impact on viral replication.

Description:

Screening will take place during the 6 weeks prior to randomisation. Eligible participants will be enrolled at week 0 and randomised to MVA HIV-B vaccine followed by vedolizumab, vedolizumab + placebo vaccine, or placebo vaccine + placebo infusions.

Participants will be randomised at each centre through web-based randomisation after entering the eligibility criteria. There will be two strata: one for those who started treatment during primary infection, and one for those who started treatment during chronic infection.

69 eligible individuals from collaborating European Countries will be enrolled, aiming for approximately half who started cART in primary infection and half who started in chronic infection. Participants continue from the screening visit (up to 6 weeks before enrolment) to the last visit, a maximum of 60 weeks (around 14 months), although follow-up will continue through to the time when virus is fully suppressed.

Treatment will be interrupted at week 18 and resumed when the viral load is confirmed to have rebounded to ≥100,000 copies/ml, or the CD4 falls to ≤350 cells/mm3, confirmed, or there is evidence of disease progression, or they have completed 24 weeks of treatment interruption.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2
• Est. completion date: July 12, 2023
• Est. primary completion date: July 12, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. HIV-1-infected

2. Aged 18 - 65 years old on the day of screening

3. Weight >50kg

4. Willing and able to provide written informed consent

5. Nadir CD4 count > 300 cells/mm3

6. CD4 count at screening > 500 cells/mm3

7. Viral load <50 copies/ml at screening.

8. Started cART after 2009 and on cART for at least one year prior to screening

9. Willing to interrupt cART for up to 24 weeks and change cART regimen if required

10. If sexually active, willing to use a reliable method of reducing the risk of transmission to their sexual partners during treatment interruption (which could include PrEP for their sexual partners)

11. If heterosexually active and able to have children, willing to use a highly effective method of contraception with partner (combined oral contraceptive pill; injectable or implanted contraceptive; IUD/IUS; physiological or anatomical sterility (in self or partner) from 2 weeks before enrolment until 18 weeks after the last injection/infusion

12. If women of childbearing potential*, willing to undergo urine pregnancy tests prior to administration of an injection and an infusion

13. Willing to avoid all other vaccines within 4 weeks of scheduled study injections

14. Willing and able to comply with visit schedule and provide blood samples

15. Being covered by medical insurance or in National Healthcare System

• A woman will be considered of childbearing potential following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

Exclusion Criteria:

1. Pregnant or lactating

2. HIV-2 infection (either isolated or associated with HIV-1)

3. VL >200 copies/ml on 2 occasions in the 12 months prior to screening

4. Previous interruptions in cART

5. Previous virological failures defined by loss of virological suppression with the presence of resistant mutations

6. Haemoglobin (Hb <12g/dL for males, <11g/dL for females)

7. Concomitant or previous conditions that preclude injection of vaccines/infusion of monoclonal antibody and PML in the past

8. History of experimental vaccinations against HIV

9. Previous treatment with chemotherapy (except for chemotherapy injected into skin lesions for Kaposi's sarcoma)

10. Treatment with systemic corticoids or immuno-suppressive agents ongoing or in the 12 weeks prior to randomisation in the trial

11. Received natalizumab or rituximab ever in the past

12. Received a TNF blocker in the past 60 days

13. Administration of an inactivated vaccine within 30 days or a live vaccine within 60 days prior to randomisation

14. Presence of a skin condition or marking that precludes inspection of the injection/infusion site

15. History of cancer (except basal cellular skin carcinoma or Kaposi's sarcoma)

16. History of significant neurological disease or cardiovascular disease (angina, myocardial infarction, transient ischemic attack, stroke); participants with controlled blood pressure are eligible

17. History of clinical autoimmune disease

18. Ongoing diseases including uncontrolled active severe infection, cardiac, pulmonary (excluding mild asthma), thyroid, renal or neurological (peripheral or central) diseases

19. Active or latent tuberculosis (unless prophylaxis in past as per local practice) - (participant must be screened for tuberculosis before starting infusions, according to routine practice)

20. Presence of pathogenic bacteria or parasites in faeces at screening

21. Participating in another biomedical research study within 30 days of randomisation

22. Known hypersensitivity to any component of the vaccine formulation used in this trial including eggs or have severe or multiple allergies to drugs or pharmaceutical agents, or any hypersensitivity to the active substance or to any of the excipients of vedolizumab.

23. Liver disease including hepatitis B (surface antigen positive) or hepatitis C (antigen or PCR positive)

24. A clinically significant abnormality on ECG

25. Hypernatraemia or hyperchloraemia

26. History of severe local or general reaction to vaccination defined as

1. local: extensive, indurated redness and swelling involving most of the arm, not resolving within 72 hours

2. general: fever >= 39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours

27. Grade 2 or worse routine laboratory parameters. Hyperbilirubinaemia to be considered an exclusion criterion only when confirmed to be conjugated bilirubinaemia

Related Conditions & MeSH terms

• Communicable Diseases
• HIV-1-infection
• Infections
• Persistent Infection

Intervention

Biological:
• Vaccine and vedolizumab (Entyvio)
Vaccine and vedolizumab infusion (Entyvio): 0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection. Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion.
• Placebo vaccine and vedolizumab infusion (Entyvio)
Placebo Vaccine: The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection. Vedolizumab infusion (Entyvio): Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion.
• Placebo vaccine and placebo infusion
Placebo Vaccine: The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection. Placebo infusion (Entyvio): 255ml Sodium Chloride (NaCl) 0.9% bag administered as an intravenous infusion over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. Participants will be observed throughout and after the infusion.

Locations

Country	Name	City	State
France	Hotel Dieu	Paris
France	Service Immunologie clinique et maladies infectieuses, Hôpital Henri Mondor	Paris	Creteil
Switzerland	Centre d'Immunothérapie et Vaccinologie, CHUV	Lausanne	Vaud
United Kingdom	St Stephens Centre, Chelsea & Westminster Hospital	London

Sponsors (19)

Lead Sponsor

Collaborator

ANRS, Emerging Infectious Diseases

Centre Hospitalier Universitaire Vaudois, Chelsea and Westminster Hospital, UK, Erasmus Medical Center, European AIDS Treatment Group (EATG), European Commission, European Georges Pompidou Hospital, EuroVacc Foundation, Henri Mondor University Hospital, Hospital Clinic of Barcelona, Imperial College London, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Istituto Nazionale Malattie Infettive Lazaro Spallanzani, Medical Research Council, Saint-Louis Hospital, Paris, France, Swiss Government, Universitätsklinikum Hamburg-Eppendorf, University College London Hospitals, University of Liverpool

Countries where clinical trial is conducted

France,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Safety outcome measures: Grade 3 or worse solicited clinical and laboratory adverse events	Occurrence of grade 3 or worse solicited clinical and laboratory adverse events	From randomisation to study completion about 54 weeks
Other	Safety outcome measures: Any adverse event leading to interruption in the vaccine/placebo or vedolizumab/placebo	Occurrence of any adverse event leading to interruption in the vaccine/placebo or vedolizumab/placebo	From randomisation to study completion about 54 weeks
Other	Safety outcome measures: Any event that results in resuming treatment during the ATI	Occurrence of any event that results in resuming treatment during the ATI	Time form treatment interruption to resuming treatment, up to 24 weeks after ATI
Other	Safety outcome measures: Serious Adverse Events	Occurrence of Serious Adverse Events	From randomisation until 30 days after the last protocol visit
Other	Safety outcome measures: Other clinical and laboratory adverse events	Occurrence of other clinical and laboratory adverse events	From randomisation to study completion about 54 weeks
Other	Safety outcome measures: Change in absolute CD4	Observation of change in absolute CD4 count	From randomisation to study completion about 54 weeks
Other	Safety outcome measures: Time to VL suppression after restarting cART	Time to VL suppression after restarting cART	From randomisation to VL suppression (= VL is undetectable (<50copies/ml)) after restarting cART until the participant returns to an undetectable viral load, about 54 weeks]
Other	Exploratory Immunological outcome measures: Characterization of vaccine induced CD4 and CD8 T-cell produced cytokine profile	Observation of vaccine induced CD4 and CD8 T-cell produced cytokines by flow cytometry	From randomisation to study completion about 54 weeks
Primary	Area under the HIV RNA curve	Area under the HIV RNA curve from treatment interruption (scheduled for 18 weeks after entering the trial)	Time from treatment interruption (scheduled for 18 weeks after entering the trial) to 24 weeks post-treatment interruption
Secondary	Virological outcome measures	Time from treatment interruption (scheduled for 18 weeks after entering the trial) to the earliest of reaching HIV RNA = 100 000 copies/ml (confirmed on a separate sample) or resuming antiretroviral therapy for any reason over a period of 24 weeks.	For participants commencing treatment interruption only, critical time points weeks 19 through to to week 42.
Secondary	Virological outcome measures	Level of HIV total RNA	From randomisation to study completion about 54 weeks
Secondary	Virological outcome measures	Cell Associated (CA) HIV RNA Quantification	From randomisation to study completion about 54 weeks
Secondary	Virological outcome measures	First local maximum (peak) level of HIV total RNA during treatment interruption	Time from treatment interruption, only in participants commencing treatment interruption, up to 24 weeks after ATI
Secondary	Virological outcome measures	Rate of increase of HIV total RNA between the last measure below the lower detection and the first local maximum	Time from treatment interruption, only in participants commencing treatment interruption, up to 24 weeks after ATI
Secondary	Virological outcome measures	Setpoint (two stable measures following a transient increase of HIV RNA)	Time from treatment interruption, only in participants commencing treatment interruption, up to 24 weeks after ATI